Recent Updates
Recently added Catalysts
PHAR Positive Sentiment Score: 80/100

Pharming Group announces results of 2026 Annual General Meeting of Shareholders

Thursday, May 28, 2026 2 min read
Key Takeaway: Pharming Group held its Annual General Meeting of Shareholders on May 28, 2026, where all proposed agenda items were approved. Key decisions included the appointment of KPMG as the independent auditor for 2026-2028 and amendments to the remuneration policy for Non-Executive Directors. Shareholders also renewed authorizations for share issuance and repurchase.

Market Sentiment Analysis

POSITIVE FACTORS

  • All proposals at the AGM were approved by shareholders.
  • KPMG was appointed as the independent auditor for three years.
  • Amendments to the remuneration policy were accepted.

Full Press Release Details

Leiden, the Netherlands, May 28, 2026:Pharming Group (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) today announced that shareholders approved all proposals presented at its Annual General Meeting of Shareholders (AGM), held earlier today.
KPMG Accountants N.V. was appointed as the Company’s independent external auditor for the financial years 2026 through 2028 (agenda item 3).
Shareholders also approved the proposals to amend the Remuneration policy for the Board of Directors regarding the fees to be paid to the Non-Executive Directors (agenda item 4), to renew the authorizations for the Board of Directors to issue shares (agenda item 5) and to repurchase shares (agenda item 6).
A recording of the webcast, the AGM presentation slides, voting results and additional information on the agenda items are available on the Company’s website under Investors/Shareholder Meetings.
About Pharming Group N.V.Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.
For more information, visitwww.pharming.comand find us onLinkedIn.
Inside InformationThis press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.
For further public information, contact:Investor RelationsMichael Levitan, VP Investor Relations and Capital MarketsT: +1 (908) 705 1696E:investor@pharming.com

Media RelationsGlobal: Saskia Mehring, Head of Corporate CommunicationsT: +31 6 28 32 60 41E:media.relations@pharming.com

U.S.: Christina Skrivan (Precision AQ on behalf of Pharming)T: +1 (636)-352-7883
Netherlands: Leon Melens (LifeSpring Life Sciences Communication on behalf of Pharming)T: +31 6 53 81 64 27

Attachment

• Pharming Group announces results 2026 AGM_EN_28MAY26

Frequently Asked Questions

What proposals were approved at Pharming's AGM?

All proposals presented at the AGM were approved by shareholders.

Who was appointed as the independent auditor?

KPMG Accountants N.V. was appointed as the independent auditor for 2026-2028.

What changes were made to the remuneration policy?

The remuneration policy for the Board of Directors regarding Non-Executive Directors' fees was amended.

Where can I find more information about the AGM?

Additional information, including a recording and voting results, is available on Pharming's website.

Tags: PHAR Viatris Investor Conferences Healthcare Pharming Group AGM shareholder meeting KPMG financial years
Last updated: May 28, 2026